Altimmune to Present at Upcoming Virtual Investor Conferences

Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) announced its participation in upcoming virtual investor conferences. These events include the Jefferies London Virtual Healthcare Conference on November 17, 2020, the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 23 to December 3, 2020, and the 3rd Annual Evercore ISI Virtual HealthCONx Conference on December 2, 2020. All sessions will be accessible through the investor relations section of Altimmune's website. The company focuses on developing intranasal vaccines and therapies for diseases, including COVID-19 and liver disease.

GAITHERSBURG, Md., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual investor conferences:

Jefferies London Virtual Healthcare Conference
Tuesday, November 17, 2020
11:25 am Eastern Time

Piper Sandler 32^nd Annual Virtual Healthcare Conference
Monday, November 23, 2020 to Thursday, December 3, 2020
Fireside chat recording available to conference participants

3^rd Annual Evercore ISI Virtual HealthCONx Conference
Wednesday, December 2, 2020
8:00 am Eastern Time

The sessions will be webcast and can be accessed by visiting the investor relations section of the company's website at www.altimmune.com under Events / Presentations.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The Company’s diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visit www.altimmune.com.

Investor Contacts:

Stacey Jurchison Altimmune, Investor Relations Phone: 410-474-8200 sjurchison@altimmune.com		Ashley R. Robinson LifeSci Advisors, LLC 617-430-7577 arr@lifesciadvisors.com

FAQ

When is Altimmune presenting at the Jefferies London Virtual Healthcare Conference?

Altimmune will present at the Jefferies London Virtual Healthcare Conference on November 17, 2020, at 11:25 am Eastern Time.

What dates is Altimmune attending the Piper Sandler 32nd Annual Virtual Healthcare Conference?

Altimmune will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 23 to December 3, 2020.

When will the 3rd Annual Evercore ISI Virtual HealthCONx Conference take place for Altimmune?

The 3rd Annual Evercore ISI Virtual HealthCONx Conference will occur on December 2, 2020, at 8:00 am Eastern Time.

Where can I access Altimmune's investor presentations?

You can access Altimmune's investor presentations by visiting the investor relations section on their website at www.altimmune.com.

What focus areas does Altimmune's pipeline cover?

Altimmune's pipeline includes intranasal vaccines and therapies for COVID-19, liver disease, anthrax, and influenza.